Bioenca Spółka Akcyjna (KRS 0000959072, NIP 7393965820) is a Polish company, headquartered in Olsztyn, Warmińsko-Mazurskie voivodeship. Bioenca operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since March 22, 2022. Bioenca's most recently reported net revenue was 0 PLN for 2025. Bioenca's operations are currently suspended.
The company is currently suspended
Suspended since December 31, 2024
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Bioenca
Identity
- Name
- Bioenca Spółka Akcyjna
- Legal form
- SPÓŁKA AKCYJNA
- Founded
- March 22, 2022
- Registry status as of
- July 25, 2026
- Latest entry
- July 25, 2026
- Founding act
- 04.02.2022 ROK, REPERTORIUM A NR 1473/2022, NOTARIUSZ MARIUSZ SOCZYŃSKI PROWADZĄCY KANCELARIĘ NOTARIALNĄ W WARSZAWIE
Articles of association history (2)
- February 4, 2022: 04.02.2022 ROK, REPERTORIUM A NR 1473/2022, NOTARIUSZ MARIUSZ SOCZYŃSKI PROWADZĄCY KANCELARIĘ NOTARIALNĄ W WARSZAWIE
- March 29, 2022: AKTEM NOTARIALNYM Z DNIA 29.03.2022R., REP. A NR 3803/2022, NOTARIUSZ MARIUSZ SOCZYŃSKI, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIENIONO §9 UST. 1 STATUTU SPÓŁKI AKTEM NOTARIALNYM Z DNIA 26.09.2022R., REP. A NR 9769/2022, NOTARIUSZ MARIUSZ SOCZYŃSKI, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIENIONO §9 UST. 1 STATUTU SPÓŁKI AKTEM NOTARIALNYM Z DNIA 26.09.2022R., REP. A NR 9772/2022, NOTARIUSZ MARIUSZ SOCZYŃSKI, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIENIONO §1 STATUTU SPÓŁKI
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. TOWAROWA, 9F, 36, 10-416, OLSZTYN, POLSKA
- Voivodeship
- WARMIŃSKO-MAZURSKIE
- District
- OLSZTYN
- BIURO@BIOENCA.PL
- Website
- WWW.BIOENCA.PL
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Bioenca
Credibility rating
5 / 100
Very poor credibility
Insolvency risk
suspended
Significant formal threat
Closure risk
80
/ 100
Extremely high risk
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/4 yrs
Board changes
0
0/4 yrs
PKD changes
0
0/4 yrs
Name changes
1
1/4 yrs
Data from 4 years of registry activity.
Credibility history
Payment reliability score from 2023–2025
Current: S (5/100)
Trend: stable (0.0 pts/year)
Spółka jest obecnie zawieszona – działalność operacyjna wstrzymana, wskaźnik wiarygodności odzwierciedla stan przed zawieszeniem.
Trade credit limit history
Standard limit from 2023–2025
Current: 0 PLN
Safe: 0 PLN
Operational status - Bioenca
Founded
March 22, 2022
4 years in operation
Legal form
SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
OLSZTYN
WARMIŃSKO-MAZURSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
111.5 K PLN
Shareholders
1
shareholder
Board
1 person
Sup. board: 3
Filed years
3 years
2023–2025 · profitable: 0/3
Registry entries
15
latest: July 25, 2026
Risk signals
Revenue
0 PLN
2025
Net profit
0 PLN
2025
Assets
273.0 K PLN
2025
Equity
251.3 K PLN
2025
EBITDA
N/A
2025
no depreciation data
Valuation
0 PLN
suspended
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Bioenca.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
